Skip to main content
S 476 118th Congress Senate Health Genetics Medicare Prescription drugs

Maintaining Investments in New Innovation Act

Introduced: June 17, 2024 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 16, 2023
Read twice and referred to the Committee on Finance.
Feb 16, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

What's happening now February 16, 2023

Read twice and referred to the Committee on Finance.

 Related & companion bills 1
  • HR 5547 Identical bill Maintaining Investments in New Innovation Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 4

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • LMH STRATEGIC SOLUTIONS
    for IONIS PHARMACEUTICALS, INC. · California · 1st Quarter (Jan 1 - Mar 31) 2025
  • TIBER CREEK HEALTH STRATEGIES, INC.
    for NOVARTIS · District of Columbia · 1st Quarter (Jan 1 - Mar 31) 2025
  • FORBES-TATE
    for NOVARTIS, INC. · District of Columbia · 1st Quarter (Jan 1 - Mar 31) 2025
  • FORBES-TATE
    for IONIS PHARMACEUTICAL, INC. · California · 1st Quarter (Jan 1 - Mar 31) 2025
 Cosponsors 3
All 3 Republican 3
R
Daines, Steve
Montana · Jun 17, 2024
 R
Budd, Ted
North Carolina · Nov 14, 2023
 R
Blackburn, Marsha
Tennessee · Feb 16, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 476: Maintaining Investments in New Innovation Act. 118th Congress. Open America. https://openamerica.io/bill/118-S-476/
MLA
"S. 476: Maintaining Investments in New Innovation Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-476/.
Bluebook (legal)
S. 476, 118th Cong. (2026), https://openamerica.io/bill/118-S-476/.
Markdown link
[S. 476: Maintaining Investments in New Innovation Act](https://openamerica.io/bill/118-S-476/)
Report a problem